Processing

Please wait...

Settings

Settings

Goto Application

1. CA2654262 - KV1.5 POTASSIUM CHANNEL INHIBITORS

Office Canada
Application Number 2654262
Application Date 19.06.2007
Publication Number 2654262
Publication Date 27.12.2007
Publication Kind A1
IPC
C07D 471/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
10Spiro-condensed systems
A61K 31/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
A61P 9/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
06Antiarrhythmics
CPC
A61P 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
A61P 9/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
A61P 9/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
06Antiarrhythmics
A61P 25/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
04Centrally acting analgesics, e.g. opioids
C07D 471/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
02in which the condensed system contains two hetero rings
10Spiro-condensed systems
Applicants WYETH
Inventors JANUSZ, JOHN MICHAEL
WU, SHENGDE
FAIRWEATHER, NEIL T.
LEE, WENLIN
BLASS, BENJAMIN E.
FLUXE, ANDREW J.
HODSON, STEPHEN J.
RIDGEWAY, JAMES M II
Priority Data 60/815,066 20.06.2006 US
Title
(EN) KV1.5 POTASSIUM CHANNEL INHIBITORS
(FR) INHIBITEURS DU CANAL POTASSIQUE KV1.5
Abstract
(EN)
The present invention relates to 4-oxo-1,3,8-triaza-spiro[4.5]decanes which are useful as Kv1.5 potassium channel inhibitors providing atrial-selective antiarrhythmic activity. The present invention further relates to compositions and methods for treating atrial-selective antiarrhythmia.

Other related publications